Articles with public access mandates - Anne-Marie Russell - Versus Arthritis, UKLearn more
NoteFor this mandate, articles should be available from specific locations.
Not available based on mandate: 3
An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study
TM Maher, E Oballa, JK Simpson, J Porte, A Habgood, WA Fahy, A Flynn, ...
The Lancet Respiratory Medicine 5 (12), 946-955, 2017
Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis
CJ Stock, H Sato, C Fonseca, WAS Banya, PL Molyneaux, H Adamali, ...
Thorax 68 (5), 436-441, 2013
Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial
D Visca, L Mori, V Tsipouri, S Fleming, A Firouzi, M Bonini, MJ Pavitt, ...
The Lancet Respiratory Medicine 6 (10), 759-770, 2018
Available based on mandate: 4
Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis
AM Russell, H Adamali, PL Molyneaux, PT Lukey, RP Marshall, ...
American journal of respiratory and critical care medicine 194 (8), 989-997, 2016
Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
MJG van Manen, SS Birring, C Vancheri, V Vindigni, E Renzoni, ...
European Respiratory Journal 50 (4), 2017
Outcome measures for clinical trials in interstitial lung diseases
M R Lammi, R P Baughman, S S Birring, AM Russell, J H Ryu, ...
Current respiratory medicine reviews 11 (2), 163-174, 2015
World Health Organization (WHO) international classification of functioning, disability and health (ICF) core set development for interstitial lung disease
LA Saketkoo, R Escorpizo, J Varga, KJ Keen, K Fligelstone, SS Birring, ...
Frontiers in Pharmacology 13, 979788, 2022
Publication and funding information is determined automatically by a computer program